Healthcare Frost Radar™: Predictive Genetic Testing Technologies, 2023

A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines

INDUSTRY
Healthcare

RELEASE DATE
16-Oct-2023
REGION
Global
DELIVERABLE TYPE
Frost Radar

RESEARCH CODE
DACC-01-00-00-00
SKU
HC_2023_223
Yes
SHARE

Frost Radar™: Predictive Genetic Testing Technologies, 2023
Published on: 16-Oct-2023 | SKU: HC_2023_223

Need more details?

$4,950.00

$3,712.50 save 25 %

DownloadLink
Need more details?

Predictive genetic testing (PGT) comprises analysis of genes, the whole genome, or exomes to predict the risk of a wide range of disorders. It can have long-term implications in preventive healthcare practices, including delayed onset of disease, treatment management, pharmacogenomics, and general wellness. One outcome of the COVID-19 pandemic has been increased focus on preventive healthcare practices from a consumer wellness perspective, and PGT technology complements this desire for preventive and personalized healthcare and wellness monitoring tools. As such, PGT platforms are likely to experience increased global uptake in the next 5 years.

Industry convergence is rising among consumer genetic testing, diagnostic, and pharma companies due to increasing focus on holistic and hyper-personalized healthcare practices. Also, collaboration with pharma and diagnostic companies is on the rise as companies look to deliver targeted therapeutic innovations. This is likely to advance new product development for precision medicine applications in the future. This Frost Radar provides insights across leading clinical and predictive consumer genetics companies that use microarrays, whole genome sequencing (WGS), whole exome sequencing (WES), and targeted sequencing platforms. Key applications areas for such technologies include pharmacogenomic, prenatal, reproductive health, newborn, hereditary cancer risks, rare disease risk, and health and wellness assessment. Emerging application areas for PGT technologies include population-scale genomics for drafting nationwide preventive healthcare guidelines.

Next-generation sequencing (NGS) technologies have high growth potential to fuel new advances in the global PGT landscape. Technology advances in artificial intelligence (AI) and machine learning (ML) platforms will help users derive actionable healthcare insights from a large pool of genomic data. Integration of these advanced technologies is also likely to fuel progress tied to improving insights across population-scale genomics studies. Leading companies in the PGT space are collaborating with pharma companies to develop precision diagnostic and therapeutic innovations. Some companies are also looking to leverage the large-scale genomic data for population genomic analyses.

Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar. The publication presents competitive profiles of each company on the Frost Radar considering their strengths and the opportunities that best fit those strengths.

Strategic Imperative

Growth Environment

Growth Environment (continued)

Frost Radar™: Predictive Genetic Testing Technologies

Frost Radar™

BGI Genomics

Myriad Genetics

Natera, Inc.

Invitae

Veritas Genetics

Ancestry

Color Health

GeneDx

23andMe

Prenetics

Strategic Insights

Significance of Being on the Frost Radar™

Frost Radar™ Empowers the CEO’s Growth Team

Frost Radar™ Empowers Investors

Frost Radar™ Empowers Customers

Frost Radar™ Empowers the Board of Directors

Frost Radar™: Benchmarking Future Growth Potential

Frost Radar™: Benchmarking Future Growth Potential

Legal Disclaimer

Frost Radar™: Benchmarking Future Growth Potential 2 Major Indices, 10 Analytical Ingredients, 1 Platform

Growth Index

Growth Index (GI) is a measure of a company’s growth performance and track record, along with its ability to develop and execute a fully aligned growth strategy and vision; a robust growth pipeline system; and effective market, competitor, and end-user focused sales and marketing strategies.

  • Market Share (previous 3 years)
    This is a comparison of a company’s market share relative to its competitors in a given market space for the previous 3 years.
  • Revenue Growth (previous 3 years)
    This is a look at a company’s revenue growth rate for the previous 3 years in the market/industry/category that forms the context for the given Frost Radar™.
  • Growth Pipeline
    This is an evaluation of the strength and leverage of a company’s growth pipeline system to continuously capture, analyze, and prioritize its universe of growth opportunities.
  • Vision and Strategy
    This is an assessment of how well a company’s growth strategy is aligned with its vision. Are the investments that a company is making in new products and markets consistent with the stated vision?
  • Sales and Marketing
    This is a measure of the effectiveness of a company’s sales and marketing efforts in helping it drive demand and achieve its growth objectives.

Innovation Index

Innovation Index (II) is a measure of a company’s ability to develop products/ services/ solutions (with a clear understanding of disruptive Mega Trends) that are globally applicable, are able to evolve and expand to serve multiple markets and are aligned to customers’ changing needs.

  • INNOVATION SCALABILITY
    This determines whether an organization’s innovations are globally scalable and applicable in both developing and mature markets, and also in adjacent and non-adjacent industry verticals.
  • RESEARCH AND DEVELOPMENT
    This is a measure of the efficacy of a company’s R&D strategy, as determined by the size of its R&D investment and how it feeds the innovation pipeline.
  • PRODUCT PORTFOLIO
    This is a measure of a company’s product portfolio, focusing on the relative contribution of new products to its annual revenue.
  • MEGATRENDS LEVERAGE
    This is an assessment of a company’s proactive leverage of evolving, long-term opportunities and new business models, as the foundation of its innovation pipeline.
  • CUSTOMER ALIGNMENT
    This evaluates the applicability of a company’s products/services/solutions to current and potential customers, as well as how its innovation strategy is influenced by evolving customer needs.

Significance of Being on the Frost Radar™

Companies plotted on the Frost RadarTM are the leaders in the industry for growth, innovation, or both. They are instrumental in advancing the industry into the future.

  • GROWTH POTENTIAL
    Your organization has significant future growth potential, which makes it a Company to Action.
  • BEST PRACTICES
    Your organization is well positioned to shape Growth Pipeline™ best practices in your industry.
  • COMPETITIVE INTENSITY
    Your organization is one of the key drivers of competitive intensity in the growth environment.
  • CUSTOMER VALUE
    Your organization has demonstrated the ability to significantly enhance its customer value proposition.
  • PARTNER POTENTIAL
    Your organization is top of mind for customers, investors, value chain partners, and future talent as a significant value provider.

Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Healthcare research

15 Sep 2026   |   Global   |   Market Research

Vendor Profiles: Advanced Wound Care Management Market, Global, 2025

The wound care market is being transformed by advanced technologies and evolving care models that focus on improving patient outcomes and reducing healthcare costs. Innovations such as smart sensor-embedded dressings, artificial intelligence (AI)-based wound imaging systems, enhanced negative pressu...

11 Sep 2026   |   Global   |   Frost Radar

Frost Radar™: Pharmaceutical Commercialization Solutions and Services, 2026

Pharmaceutical commercialization is a multidimensional concept in the successful launch and distribution of a drug. The process includes the development of a pricing strategy that reflects the drug’s value, negotiation with payers to ensure drug cost coverage, regulatory compliance, and the generati...

07 Sep 2026   |   Global   |   Technology Research

Synthetic Antibodies and AI-Optimized Immunotherapies

Artificial intelligence is becoming increasingly relevant to antibody discovery and immunotherapy development, supporting target identification, de novo antibody design, antibody engineering, clinical intelligence, and bioprocessing. Advances in generative AI, protein language models, diffusion mode...

28 Aug 2026   |   Global   |   Technology Research

Innovations and Growth Opportunities in Advanced Medical Devices, Artificial Intelligence Solutions, Digital Solutions, and Medical Imaging Solutions

The latest issue of Advanced MedTech Technology Opportunity Engine (TOE) spotlights a diverse slate of innovations across advanced medical devices, artificial intelligence solutions, digital solutions, and medical imaging solutions.The issue features advanced medical devices such as active bioelectr...

27 Aug 2026   |   Global   |   Frost Radar

Frost Radar: AI-Powered Molecular Diagnostics, 2026

AI-powered molecular diagnostics is an emerging and moderately fragmented industry that includes molecular diagnostics companies, precision medicine platforms, sequencing specialists, AI-driven analytics providers, and disease-focused biotechnology companies. No single company has dominated, present...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

Predictive genetic testing (PGT) comprises analysis of genes, the whole genome, or exomes to predict the risk of a wide range of disorders. It can have long-term implications in preventive healthcare practices, including delayed onset of disease, treatment management, pharmacogenomics, and general wellness. One outcome of the COVID-19 pandemic has been increased focus on preventive healthcare practices from a consumer wellness perspective, and PGT technology complements this desire for preventive and personalized healthcare and wellness monitoring tools. As such, PGT platforms are likely to experience increased global uptake in the next 5 years. Industry convergence is rising among consumer genetic testing, diagnostic, and pharma companies due to increasing focus on holistic and hyper-personalized healthcare practices. Also, collaboration with pharma and diagnostic companies is on the rise as companies look to deliver targeted therapeutic innovations. This is likely to advance new product development for precision medicine applications in the future. This Frost Radar provides insights across leading clinical and predictive consumer genetics companies that use microarrays, whole genome sequencing (WGS), whole exome sequencing (WES), and targeted sequencing platforms. Key applications areas for such technologies include pharmacogenomic, prenatal, reproductive health, newborn, hereditary cancer risks, rare disease risk, and health and wellness assessment. Emerging application areas for PGT technologies include population-scale genomics for drafting nationwide preventive healthcare guidelines. Next-generation sequencing (NGS) technologies have high growth potential to fuel new advances in the global PGT landscape. Technology advances in artificial intelligence (AI) and machine learning (ML) platforms will help users derive actionable healthcare insights from a large pool of genomic data. Integration of these advanced technologies is also likely to fuel progress tied to improving insights across population-scale genomics studies. Leading companies in the PGT space are collaborating with pharma companies to develop precision diagnostic and therapeutic innovations. Some companies are also looking to leverage the large-scale genomic data for population genomic analyses. Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar. The publication presents competitive profiles of each company on the Frost Radar considering their strengths and the opportunities that best fit those strengths.
More Information
Deliverable Type Frost Radar
Author Vandana Iyer
Industries Healthcare
No Index No
Is Prebook No
Keyword 1 Predictive Testing Innovations
Keyword 2 Genetic Testing Industry Trends
Keyword 3 Genetic Diagnostics Research Reports
Podcast No
WIP Number DACC-01-00-00-00

Frost Radar™: Predictive Genetic Testing Technologies, 2023

$4,950.00

Special Price $3,712.50 save 25 %

In stock
SKU
HC_2023_223